Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Front Immunol. 2024 Sep 19;15:1453220. doi: 10.3389/fimmu.2024.1453220. eCollection 2024.
Lung adenocarcinoma (LUAD), characterized by a low 5-year survival rate, is the most common and aggressive type of lung cancer. Recent studies have shown that tertiary lymphoid structures (TLS), which resemble lymphoid structures, are closely linked to the immune response and tumor prognosis. The functions of the tertiary lymphoid structure-related genes (TLS-RGs) in the tumor microenvironment (TME) are poorly understood. Based on publicly available data, we conducted a comprehensive study of the function of TLS-RGs in LUAD. Initially, we categorized LUAD patients into two TLS and two gene subtypes. Subsequently, risk scores were calculated, and prognostic models were constructed using seven genes (CIITA, FCRL2, GBP1, BIRC3, SCGB1A1, CLDN18, and S100P). To enhance the clinical application of TLS scores, we have developed a precise nomogram. Furthermore, drug sensitivity, tumor mutational burden (TMB), and the cancer stem cell (CSC) index were found to be substantially correlated with the TLS scores. Single-cell sequencing results reflected the distribution of TLS-RGs in cells. Finally, we took the intersection of overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) prognosis-related genes and then further validated the expression of these genes by qRT-PCR. Our in-depth investigation of TLS-RGs in LUAD revealed their possible contributions to the clinicopathological features, prognosis, and characteristics of TME. These findings underscore the potential of TLS-RGs as prognostic biomarkers and therapeutic targets for LUAD, thereby paving the way for personalized treatment strategies.
肺腺癌(LUAD)是最常见且侵袭性最强的肺癌类型,其五年生存率较低。最近的研究表明,三级淋巴结构(TLS)与淋巴结构相似,与免疫反应和肿瘤预后密切相关。TLS 相关基因(TLS-RGs)在肿瘤微环境(TME)中的功能仍不清楚。基于公开可用的数据,我们对 LUAD 中 TLS-RGs 的功能进行了全面研究。首先,我们将 LUAD 患者分为两种 TLS 和两种基因亚型。随后,计算了风险评分,并使用七个基因(CIITA、FCRL2、GBP1、BIRC3、SCGB1A1、CLDN18 和 S100P)构建了预后模型。为了增强 TLS 评分的临床应用,我们开发了一个精确的列线图。此外,药物敏感性、肿瘤突变负担(TMB)和癌症干细胞(CSC)指数与 TLS 评分有显著相关性。单细胞测序结果反映了 TLS-RGs 在细胞中的分布。最后,我们取了总生存期(OS)、疾病特异性生存期(DSS)和无进展生存期(PFI)预后相关基因的交集,然后通过 qRT-PCR 进一步验证了这些基因的表达。我们对 LUAD 中 TLS-RGs 的深入研究揭示了它们对临床病理特征、预后和 TME 特征的可能贡献。这些发现强调了 TLS-RGs 作为 LUAD 预后生物标志物和治疗靶点的潜力,从而为个性化治疗策略铺平了道路。